We recently developed an online tool, which enables investigators to determine the prognostic value of genes in >20 data sets with clinical annotation.43 With the TCGA breast cancer data set, higher expression of NSD1 showed a trend toward better overall survival when all tumor subtypes were considered (Figure 6c) and significant survival advantage in HER2-negative patients (135 high and 134 low expression cases, Figure 6d). This evidence concerns the gene ERBB2 and breast cancer.